Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Colorectal Neoplasms 2Adenomatous Polyposis Coli 2Lymphoma, Mantle-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Duodenal Neoplasms 1Attenuated familial adenomatous polyposis 1

Interventions

Rituximab 30acalabrutinib 15ibrutinib 13Cyclophosphamide 13Lenalidomide 12CT-P10 12zanubrutinib 9venetoclax 9Magnetic Resonance Spectroscopy 9Specimen Handling 8obinutuzumab 7Cytarabine 7Biopsy 7Bendamustine Hydrochloride 7pirtobrutinib 6glofitamab 6fludarabine 6fludarabine phosphate 5Peripheral Blood Stem Cell Transplantation 5Cyclosporine 5brexucabtagene autoleucel 4Whole-Body Irradiation 4Vincristine 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4Stem Cell Transplantation 3Sirolimus 3Methotrexate 3Cyclosporins 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Mantle-Cell × Endoscopy, Gastrointestinal × 90 days × Clear all
NCT06839053 2026-04-22

Sonrotoclax, Rituximab, and Zanubrutinib in Treating Participants With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma

Fred Hutchinson Cancer Center

Phase 2 Recruiting
30 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡